CYTO: Multiplikator P/S Auris Medical
Demand for targeted drug delivery to the brain and auditory system is driving the recruitment of specialized experts at Altamira Therapeutics (CYTO). The price-to-sales valuation exhibits volatility, while 4.40 shows the value of this parameter. Growth prospects are based on OligoPhore patents for cancer treatment, although slow product rollouts and competition in nasal agents limit the business's defensive moats.
Rincian metrik lan analitis perusahaan Altamira Therapeutics (CYTO)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data ekuitas miturut neraca:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Altamira Therapeutics|CYTO - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas altamiratherapeutics.com|CYTO - Gunggung utang perusahaan|Utang-utang marang aset resik Auris Medical|CYTO - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Altamira Therapeutics|Rasio cepet altamiratherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
CYTO - Penghasilan resik|Penghasilan resik sing dikarepake Altamira Therapeutics|CYTO - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep altamiratherapeutics.com|CYTO - Pangali PEG|Nilai bisnis marang bathi operasional sadurunge panyusutan Auris Medical|CYTO - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Altamira Therapeutics|CYTO - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan altamiratherapeutics.com|CYTO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Altamira Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis umum perusahaan:CYTO, Altamira Therapeutics Ltd
The P/S multiple determines the market value of a business per unit of generated revenue, allowing for an assessment of the premium paid for an asset relative to its actual sales. By analyzing the price-to-sales ratio dynamics, an investor compares the valuation of Altamira Therapeutics (CYTO) with the efficiency of its ESG-oriented RNA therapy developments and the transparency of its clinical processes to avoid purchasing an overvalued asset.
Pesaing Altamira Therapeutics
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KVUE (Kenvue)|Multiplikator P/S Verona Pharma PLC VRNA|MENS - Rasio rega marang pendapatan|LGND: Rasio rega marang pendapatan|AMRX (Amneal Pharmaceuticals) - Kapitalisasi marang pendapatan|PRGO: Kapitalisasi marang volume dodolan|ALVO (Alvotech SA) - Multiplikator P/S|Multiplikator P/S Liquidia Corp|Rasio rega marang pendapatan Galapagos Genomics (GLPG)|Kapitalisasi marang pendapatan ANI Pharmaceuticals Corp ANIP|Multiplikator P/S MNKD (MannKind Corporation)|Koefisien rega marang pendapatan amphastar.com (AMPH)|PCRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SPRY (ARS Pharmaceuticals Inc)|TBPH: Multiplikator P/S|Aquestive Corp (AQST) - Multiplikator P/S|Kapitalisasi marang pendapatan SCPH|TECX: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan TNXP (Tonix Pharmaceuticals Holding Corp.)|Kapitalisasi marang volume dodolan SXTC|Multiplikator P/S EPRX (Eupraxia Pharmaceuticals Inc.)|Rasio kapitalisasi pasar marang pendapatan BHST|eXoZymes Inc - Multiplikator P/S|Rega marang dodolan Oramed Pharmaceuticals|enterabio.com (ENTX) - Rasio rega marang pendapatan|MindWalk Holdings, Inc. - Rasio kapitalisasi pasar marang pendapatan|ABVC (ABVC BioPharma Inc) - Multiplikator P/S|Multiplikator P/S Cumberland Corp|Rasio rega marang pendapatan Quantum BioPharma Ltd (QNTM)|FGEN: Rasio rega marang dodolan|Multiplikator P/S TELO (Telomir Pharmaceuticals, Inc.)|Rani Therapeutics Holdings (RANI) - Rega marang dodolan|SNYR: Kapitalisasi marang pendapatan|RLYB - Multiplikator P/S|LEXX (lexariabioscience.com) - Kapitalisasi marang pendapatan|PULM: Kapitalisasi marang volume dodolan|PTHL (Pheton Holdings Limited) - Multiplikator P/S|Aptorum (APM) - Koefisien rega marang pendapatan|Multiplikator P/S LYRA|Kapitalisasi marang pendapatan Impact BioMedical, Inc. IBO|Rasio rega marang pendapatan TNF Pharmaceuticals, Inc. TNFA|Koefisien rega marang pendapatan cbdMD Inc. (YCBD)|PainReform - Multiplikator P/S|Lipella Pharmaceuticals Inc (LIPO) - Kapitalisasi marang pendapatan|OPTN (Optinose) - Kapitalisasi marang pendapatan|Rega marang dodolan Pieris Pharma (PIRS)|Kapitalisasi marang pendapatan PROC|PTPI (petrospharma.com) - Kapitalisasi marang volume dodolan|Rasio rega marang pendapatan Qilian International Holding (QLI)|SLRN - Rega marang dodolan|Rasio rega marang pendapatan TFF Pharma TFFP
